Radiopharmaceuticals for WBAMC
Closed Pre-Solicitation Posted
This opportunity was awarded. See the award notice from , or the latest solicitation from .
- Solicitation number
- PANHCA-25-P-0000-008782
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Fort Bliss, Texas 79918, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of the Army Medical Command through the Medical Readiness Contracting Office-West (MRCO-W) at Fort Bliss, Texas, is conducting market research for a radiopharmaceuticals contract to support the Department of Nuclear Medicine at William Beaumont Army Medical Center (WBAMC). The procurement seeks five specific radiopharmaceutical products: DAT SCAN (Ioflupane I123) for Parkinson's disease diagnosis, INDIUM OXINE for diagnosing infections of unknown origins, CERETEC KIT for brain disorder and dementia diagnosis, ADREVIEW for tumor diagnosis, and INDIUM DTPA IN-111 for spinal cord leak and brain swelling diagnosis. This sources sought notice aims to determine if responsible sources exist and whether the procurement can be successfully competed or set aside for small businesses under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) with a 1,300 employee size standard. The government is interested in responses from all businesses including large enterprises and small business concerns certified as 8(a), Service-Disabled Veteran-Owned, HubZone, and Women-Owned. Responses to this market research notice are due by August 26, 2025.
This procurement does not include any set-aside designations at this time, as the government is using this market research to determine the appropriate acquisition strategy. The contract period of performance is scheduled from October 1, 2025, through September 30, 2026, representing a one-year base period. No incumbent contractors or current service providers are mentioned in the notice, nor are any specific award values or budget ranges disclosed. The notice does not specify quantities for the radiopharmaceutical products being procured, focusing instead on identifying capable sources in the marketplace. This pre-solicitation notice serves purely as a planning tool and does not constitute a commitment by the government to issue a formal solicitation. The government emphasizes this is market research only and should not be interpreted as a guarantee of future contracting opportunities.
Notice text
The purpose of this sources sought notice is to conduct market research to determine if responsible sources exist by determining if this effort can be successfully competed and/or set-aside for Small Businesses. The proposed North American Industry Classification System (NAICS) Code is 325412 – Pharmaceutical Preparation Manufacturing, 1,300 employees. The Government will use this information to determine the best acquisition strategy for this procurement. The Government is interested in all large and small businesses to include 8(a), Service-Disabled Veteran-Owned, HubZone, and Women-Owned small business concerns.
The Medical Readiness Contracting Office-West (MRCO-W), Fort Bliss, Texas, is seeking potential sources to establish a radiopharmaceuticals contract for the Department of Nuclear Medicine at William Beaumont Army Medical Center (WBAMC), Fort Bliss, Texas.
This requirement is for the purchase of:
DAT SCAN (Ioflupane I123) - This radio pharmaceutical used to diagnose Parkison disease.
INDIUM OXINE-This radio pharmaceutical combined with a patient’s white blood cells used to diagnose infections of unknown origins.
CERETEC KIT - This cold kit when combined with radioactive Tc99m under sterile compounding forms a radio pharmaceutical used to diagnose brain disorders dementia and evaluated a patient for brain death. Also combined with radioactive Tc99m and a patient’s white blood cells can look for infections of unknown origins.
ADREVIEW - This radio pharmaceutical used to diagnose pheochromocytoma or neuroblastoma (types of tumors)
INDIUM DTPA IN-111 - This radio pharmaceutical used to diagnose spinal cord leaks and swelling in the brain is delivered through an injection directly into the spinal canal by a board-certified physician.
Period of Performance: 1 October 2025 - 30 September 2026.
This is not a solicitation. This information is for planning purposes only and is not to be construed as a commitment by the government, implied or otherwise, to issue a solicitation or award a contract. Contractors responding to this sources-sought notice are advised their response does not ensure participation in future solicitations or contract awards. The government will not reimburse any company or individual for any expense associated with preparation or participation in this research. Interested parties should e-mail responses to troy.a.loge.civ@health.mil.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Radiopharmaceuticals for WBAMC | Award Notice | |
| Radiopharmaceuticals for WBAMC | Solicitation | |
| Radiopharmaceuticals for WBAMC | Solicitation | |
| Radiopharmaceuticals for WBAMC | Pre-Solicitation | |
| This notice | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 6505--FY27 Low Energy General Radiopharmaceuticals 36C25027Q0052 | Veterans Integrated Service Network 10 | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity